AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at Alithea Genomics,… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Dr Paul Finn, Chief Scientific Officer at Oxford Drug Design, explores the current use of AI in drug discovery and where the technology falls short. Nobody can have failed to notice the rapid entry of AI into many aspects of our daily lives; as a source of… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More
Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More
Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More
Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More
AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027. Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous… Read More
